COVID-19 updates - Get the latest information about Coronavirus and Iowa Heart Center

Vesalius CV

Purpose of Study

To evaluate the effect of treatment with evolocumab, compared to placebo, on the risk for coronary heart disease, death, myocardial infarction, or ischemic stroke

Trial Status

Enrolling

Eligibility Criteria

Must be > 50 years (men), or > 55 years (women), LDL-C > 100 mg/dl, significant coronary artery disease, peripheral arterial disease, or diabetes mellitus

Duration of Participation

Approximately 4 years

Contact Name: Lindsay Risk

Contact Phone: 515-633-3847

Contact Email: lirisk@iowaheart.com